Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School students. A student asked if the stock, given the company’s reputation for ...

Pfizer Inc. (NYSE:PFE) is one of the latest stocks on Jim Cramer’s radar. Cramer noted that the company could not perform as ...

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Pfizer beat earnings expectations decisively this morning, with shares of PFE gapping up more than 12% in pre-market trading.

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

NEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Tuesday reported third-quarter profit of $3.54 billion. On a per-share basis, the New York-based company said it had net income of 62 cents.

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the ...